Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trilostane · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Trilostane | DRUG | Taken orally once a day for three days then twice daily thereafter. |
| Hydrocortisone | DRUG | Taken orally with trilostane. |
Inclusion Criteria: * Histologically confirmed prostate adenocarcinoma * Disease progression despite androgen depravation therapy and antiandrogen withdrawal * Progressive measurable disease or bone scan progression or PSA progression * Serum total testosterone \< 50ng/ml * Creatinine \< 2.0 mg/dl ...
Top 20 of 55 competitors
Trilostane is being studied in prostate cancer, specifically androgen-independent prostate cancer and prostate adenocarcinoma. It is an investigational small molecule developed by Sanofi. A Phase 2 trial evaluated it in adult male patients with these conditions. It is not described as an approved treatment for prostate cancer.
Trilostane targets HSD3B2, also known as 3 beta-hydroxysteroid dehydrogenase type 2. It acts as an inhibitor of this enzyme. By inhibiting HSD3B2, Trilostane affects steroid hormone synthesis, which is the basis for its investigation in hormone-related cancers such as prostate cancer.
Sanofi, ticker SNY, is the developer of Trilostane. The company is associated with the drug's clinical development in oncology, including the Phase 2 study in prostate cancer. Sanofi is a global pharmaceutical company.
Trilostane is in Phase 2 clinical development for prostate cancer. One Phase 2 trial has been completed, and no active trials are currently listed. It remains an investigational agent and is not described as FDA approved for this indication.
Trilostane has been studied in one completed Phase 2 trial, NCT00181597, titled "Trilostane for Androgen-Independent Prostate Cancer." The trial enrolled 24 male patients aged 18 years and older in the United States. It was an uncontrolled, non-randomized study.